PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) shot up 1.5% on Thursday . The company traded as high as $1.80 and last traded at $1.66. 11,569 shares were traded during mid-day trading, an increase of 31% from the average session volume of 8,831 shares. The stock had previously closed at $1.63.
PharmaCyte Biotech Stock Down 8.4 %
The firm has a fifty day moving average price of $1.69 and a 200-day moving average price of $1.79.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
See Also
- Five stocks we like better than PharmaCyte Biotech
- What Investors Need to Know About Upcoming IPOs
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What is a buyback in stocks? A comprehensive guide for investors
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
